Market news

2026-09-24. The following slide deck was published by Rapid Micro Biosystems, Inc.

Rapid Micro Biosystems (RPID) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Detailed price information for Rapid Micro Biosystems Inc Cl A (RPID-Q) from The Globe and Mail including charting and trades.

Rapid Micro Biosystems (RPID) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Detailed price information for Rapid Micro Biosystems Inc Cl A (RPID-Q) from The Globe and Mail including charting and trades.

Reports second quarter 2026 total revenue of $8.1 million, representing 11% growth compared to the second quarter of 2025 Achieved a significant milestone with the 200th Growth Direct system placed globally; placed four Growth Direct systems and completed nine validations in the second quarter 2026Second quarter consumable revenue increased more than 20% year-over-yearSecond quarter recurring revenue increased 14% year-over-year; comprised 63% of total revenue Reports record second quarter total

LEXINGTON, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced the grants on August 3, 2026, of 90,000 restricted stock units (“RSUs”) of the Company’s Class A common stock (“Common Stock”) and a non-qualified stock option to purchase 170,000 shares

LEXINGTON, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release second quarter 2026 financial results prior to the market open on Friday, August 7, 2026. In conjunction with the release, the Company’s management team will host a webcast conference call a

Gainers EUDA Health Holdings (NASDAQ:EUDA) shares rose 22.3% to $15.2 during Friday's regular session. Forte Biosciences (NASDAQ:FBRX) shares moved upwards by 18.39% to $43.45. The market value of their